Analysis of CD16+ CD56dim NK cells from CLL patients: Evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies

10.1038/leu.2010.240

Saved in:

Bibliographic Details
Main Authors:	Le Garff-Tavernier, M, Decocq, J, De Romeuf, C, Parizot, C, Dutertre, C.A, Chapiro, E, Davi, F, Debré, P, Prost, J.F, Teillaud, J.L, Merle-Beral, H, Vieillard, V
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Article
Published:	Nature Publishing Group 2020
Subjects:	antineoplastic agent CD16 antigen CD20 antibody CD56 antigen Fc receptor IIa lfb r 603 natural killer cell receptor rituximab unclassified drug Fc receptor FCGR3B protein, human glycosylphosphatidylinositol anchored protein LFB R603 LFB-R603 monoclonal antibody NCAM1 protein, human adult aged antineoplastic activity article autologous hematopoietic stem cell transplantation B lymphocyte chronic lymphatic leukemia cytokine production cytotoxicity degranulation disease course female human in vitro study low drug dose major clinical study male natural killer cell priority journal protein expression antibody dependent cellular cytotoxicity immunology immunophenotyping middle aged Adult Aged Aged, 80 and over Antibodies, Monoclonal Antibodies, Monoclonal, Murine-Derived Antibody-Dependent Cell Cytotoxicity Antigens, CD56 Antineoplastic Agents Female GPI-Linked Proteins Humans Immunophenotyping Killer Cells, Natural Leukemia, Lymphocytic, Chronic, B-Cell Male Middle Aged Receptors, IgG
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/180977
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-180977
record_format	dspace
spelling	sg-nus-scholar.10635-1809772023-08-29T22:04:25Z Analysis of CD16+ CD56dim NK cells from CLL patients: Evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies Le Garff-Tavernier, M Decocq, J De Romeuf, C Parizot, C Dutertre, C.A Chapiro, E Davi, F Debré, P Prost, J.F Teillaud, J.L Merle-Beral, H Vieillard, V DUKE-NUS MEDICAL SCHOOL antineoplastic agent CD16 antigen CD20 antibody CD56 antigen Fc receptor IIa lfb r 603 natural killer cell receptor rituximab unclassified drug antineoplastic agent CD56 antigen Fc receptor FCGR3B protein, human glycosylphosphatidylinositol anchored protein LFB R603 LFB-R603 monoclonal antibody NCAM1 protein, human rituximab adult aged antineoplastic activity article autologous hematopoietic stem cell transplantation B lymphocyte chronic lymphatic leukemia cytokine production cytotoxicity degranulation disease course female human in vitro study low drug dose major clinical study male natural killer cell priority journal protein expression antibody dependent cellular cytotoxicity chronic lymphatic leukemia immunology immunophenotyping middle aged natural killer cell Adult Aged Aged, 80 and over Antibodies, Monoclonal Antibodies, Monoclonal, Murine-Derived Antibody-Dependent Cell Cytotoxicity Antigens, CD56 Antineoplastic Agents Female GPI-Linked Proteins Humans Immunophenotyping Killer Cells, Natural Leukemia, Lymphocytic, Chronic, B-Cell Male Middle Aged Receptors, IgG 10.1038/leu.2010.240 Leukemia 25 1 101-109 2020-10-27T06:47:19Z 2020-10-27T06:47:19Z 2011 Article Le Garff-Tavernier, M, Decocq, J, De Romeuf, C, Parizot, C, Dutertre, C.A, Chapiro, E, Davi, F, Debré, P, Prost, J.F, Teillaud, J.L, Merle-Beral, H, Vieillard, V (2011). Analysis of CD16+ CD56dim NK cells from CLL patients: Evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia 25 (1) : 101-109. ScholarBank@NUS Repository. https://doi.org/10.1038/leu.2010.240 0887-6924 https://scholarbank.nus.edu.sg/handle/10635/180977 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Nature Publishing Group Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	antineoplastic agent CD16 antigen CD20 antibody CD56 antigen Fc receptor IIa lfb r 603 natural killer cell receptor rituximab unclassified drug antineoplastic agent CD56 antigen Fc receptor FCGR3B protein, human glycosylphosphatidylinositol anchored protein LFB R603 LFB-R603 monoclonal antibody NCAM1 protein, human rituximab adult aged antineoplastic activity article autologous hematopoietic stem cell transplantation B lymphocyte chronic lymphatic leukemia cytokine production cytotoxicity degranulation disease course female human in vitro study low drug dose major clinical study male natural killer cell priority journal protein expression antibody dependent cellular cytotoxicity chronic lymphatic leukemia immunology immunophenotyping middle aged natural killer cell Adult Aged Aged, 80 and over Antibodies, Monoclonal Antibodies, Monoclonal, Murine-Derived Antibody-Dependent Cell Cytotoxicity Antigens, CD56 Antineoplastic Agents Female GPI-Linked Proteins Humans Immunophenotyping Killer Cells, Natural Leukemia, Lymphocytic, Chronic, B-Cell Male Middle Aged Receptors, IgG
spellingShingle	antineoplastic agent CD16 antigen CD20 antibody CD56 antigen Fc receptor IIa lfb r 603 natural killer cell receptor rituximab unclassified drug antineoplastic agent CD56 antigen Fc receptor FCGR3B protein, human glycosylphosphatidylinositol anchored protein LFB R603 LFB-R603 monoclonal antibody NCAM1 protein, human rituximab adult aged antineoplastic activity article autologous hematopoietic stem cell transplantation B lymphocyte chronic lymphatic leukemia cytokine production cytotoxicity degranulation disease course female human in vitro study low drug dose major clinical study male natural killer cell priority journal protein expression antibody dependent cellular cytotoxicity chronic lymphatic leukemia immunology immunophenotyping middle aged natural killer cell Adult Aged Aged, 80 and over Antibodies, Monoclonal Antibodies, Monoclonal, Murine-Derived Antibody-Dependent Cell Cytotoxicity Antigens, CD56 Antineoplastic Agents Female GPI-Linked Proteins Humans Immunophenotyping Killer Cells, Natural Leukemia, Lymphocytic, Chronic, B-Cell Male Middle Aged Receptors, IgG Le Garff-Tavernier, M Decocq, J De Romeuf, C Parizot, C Dutertre, C.A Chapiro, E Davi, F Debré, P Prost, J.F Teillaud, J.L Merle-Beral, H Vieillard, V Analysis of CD16+ CD56dim NK cells from CLL patients: Evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
description	10.1038/leu.2010.240
author2	DUKE-NUS MEDICAL SCHOOL
author_facet	DUKE-NUS MEDICAL SCHOOL Le Garff-Tavernier, M Decocq, J De Romeuf, C Parizot, C Dutertre, C.A Chapiro, E Davi, F Debré, P Prost, J.F Teillaud, J.L Merle-Beral, H Vieillard, V
format	Article
author	Le Garff-Tavernier, M Decocq, J De Romeuf, C Parizot, C Dutertre, C.A Chapiro, E Davi, F Debré, P Prost, J.F Teillaud, J.L Merle-Beral, H Vieillard, V
author_sort	Le Garff-Tavernier, M
title	Analysis of CD16+ CD56dim NK cells from CLL patients: Evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
title_short	Analysis of CD16+ CD56dim NK cells from CLL patients: Evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
title_full	Analysis of CD16+ CD56dim NK cells from CLL patients: Evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
title_fullStr	Analysis of CD16+ CD56dim NK cells from CLL patients: Evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
title_full_unstemmed	Analysis of CD16+ CD56dim NK cells from CLL patients: Evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
title_sort	analysis of cd16+ cd56dim nk cells from cll patients: evidence supporting a therapeutic strategy with optimized anti-cd20 monoclonal antibodies
publisher	Nature Publishing Group
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/180977
_version_	1779152733175021568

Analysis of CD16+ CD56dim NK cells from CLL patients: Evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies

Similar Items